Regeneron Pharmaceuticals Inc (REGN)
Cash ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 2,730,000 | 2,152,300 | 1,937,200 | 3,916,300 | 3,105,900 | 3,491,300 | 3,395,100 | 3,345,700 | 2,885,600 | 3,432,400 | 2,072,200 | 1,437,900 | 2,193,700 | 1,573,000 | 1,992,200 | 2,208,200 | 1,617,800 | 1,384,800 | 1,045,500 | 1,708,500 |
Short-term investments | US$ in thousands | 8,114,800 | 7,761,300 | 6,990,500 | 5,043,400 | 4,636,400 | 3,530,400 | 4,171,300 | 3,704,900 | 2,809,100 | 2,355,200 | 1,838,600 | 2,065,900 | 1,393,300 | 1,452,900 | 1,152,000 | 1,795,200 | 1,596,500 | 1,493,100 | 1,624,200 | 1,523,900 |
Total current liabilities | US$ in thousands | 3,423,400 | 3,598,600 | 3,104,400 | 3,100,100 | 3,141,300 | 2,879,200 | 3,033,900 | 3,007,600 | 3,932,500 | 3,714,800 | 3,732,400 | 3,217,800 | 2,697,400 | 2,337,800 | 3,702,400 | 2,055,200 | 2,096,600 | 1,765,400 | 1,713,100 | 1,511,400 |
Cash ratio | 3.17 | 2.75 | 2.88 | 2.89 | 2.46 | 2.44 | 2.49 | 2.34 | 1.45 | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,730,000K
+ $8,114,800K)
÷ $3,423,400K
= 3.17
The cash ratio for Regeneron Pharmaceuticals, Inc. has demonstrated a positive trend over the past eight quarters, indicating the company's strong ability to cover its short-term liabilities with cash and cash equivalents. The ratio has consistently been above 2, reflecting a healthy liquidity position for the company.
The highest cash ratio was observed in Q4 2023 at 3.28, suggesting a significant increase in the company's ability to settle its short-term obligations using its available cash resources. This indicates that the company has a substantial amount of cash on hand relative to its current liabilities.
Overall, the trend in the cash ratio for Regeneron Pharmaceuticals, Inc. indicates a strong financial position with healthy liquidity levels. It suggests that the company has the ability to meet its short-term financial obligations without the need for additional borrowing or liquidation of long-term assets.
Peer comparison
Dec 31, 2023